Some chemical entities are available. Pharmaceutical equipment acceptable on at least one chemical substance and one or more drugs is also provided. It describes methods for treating patients with diseases and disorders that inhibit kmo activity, including at least providing these patients with an effective chemical to reduce symptoms or symptoms of the disease or disorder. These include neurodegenerative diseasesIt's like Huntington's disease It also describes treatment methods, including the management of at least one chemical entity as a single active agent, or at least one chemical entity with one or more different therapeutic agents. Methods for selecting compounds capable of inhibiting kmo activity are also provided. 1. Characteristic 1: at least one chemical entity selected from formula compound (1) has acceptable salts and reagents, where x and y are independent of n-y-ch -.The condition is that at least one X and Y is - N；R1 is arilo, or monocyclic pagan, each of which is replaced by the first set of z-r8310a equations；If you are already registered, please log in first.- yes.-S (O) --S (O) --1...-1-Nr-3- No. first-1-1-3y -C (O) -There, R1,R2,and R¹³ are independently selected from hydrogen, lower alkyl, hydroxyl, and lower alkoxy； R⁶ is selected from hydrogen, optionally substituted C₁₋₆ alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocycloalkyl, provided that if Z is -O-,So r83100a is not a substitute benzene, or a substitute pyridinol, or r8310y R1 3,taken together with the nitrogen to which they are attached, they form an optionally substituted 5- to 7-membered heterocycloalkyl ring, and a second group selected from halogen and lower alkyl optionally substituted with halogen, or R¹ is selected from 2,3-dihydrobenzofuran-5- ilo, chroman-6-yl, 1,3-benzodioxol-5-yl, 2,3-dihydro-1,4-benzodioxin-6-yl, 1,3-benzoxazol-5-yl, benzoimidazol-5-yl, 1,3-benzoxazol-6-yl, 2-oxo-2
